Dr. Anne Mills is an Associate Professor of Pathology at the University of Virginia in Charlottesville, Virginia. She is a general surgical pathologist and cytopathologist with subspecialty focus on gynecologic and breast pathology. She serves as the AP/CP Residency Director as well as the Gynecologic and Breast Pathology Fellowship Director. Her research centers on translational investigations of biomarkers in endometrial, ovarian, cervical, and breast malignancies. In particular, she is interested in HPV-associated neoplasia, familial cancer syndromes, and the pathologist’s role in pairing cancers with targeted treatments such as tyrosine kinase inhibitors and immunotherapy. She has published 89 original research articles and chapters on these and related topics, and her work has been cited over 1650 times. Outside of work she enjoys trail running, Peloton biking, scuba diving, and spending time with her husband and two children.
This session will review the rationale behind anti-PD-1 checkpoint inhibitor therapy in cervical and vulvar carcinomas and describe how PD-L1 immunohistochemical staining is used as a predictive biomarker in these tumors. Alternate approved biomarkers for anti-PD-1 therapy across all solid tumors, such as mismatch repair deficiency and tumor mutational burden, will also be briefly discussed. The session will conclude with a discussion of possible reasons for limited response to immunotherapy in these tumors and an introduction to emerging biomarkers that may improve patient selection in the future.
1. Cite trials leading to anti-PD-1 approval in cervical carcinoma.
2. Score PD-L1 immunohistochemistry in cervical carcinoma.